Rafaël Fonseca
YOU?
Author Swipe
View article: QUALIDADE 4.0: UMA REVISÃO DA LITERATURA SOBRE AS TECNOLOGIAS EMERGENTES E SUA INTEGRAÇÃO COM AS METODOLOGIAS CLÁSSICAS
QUALIDADE 4.0: UMA REVISÃO DA LITERATURA SOBRE AS TECNOLOGIAS EMERGENTES E SUA INTEGRAÇÃO COM AS METODOLOGIAS CLÁSSICAS Open
View article: Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma
Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma Open
Cyclin D1, encoded by CCND1, is a cell cycle regulator, overexpressed in ~15% of multiple myeloma (MM) cases via CCND1::IGH super-enhancer juxtaposition through t(11;14). Cyclin D1 also plays a non-canonical role in transcriptional regulat…
View article: Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples
Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples Open
Background: Minimal residual disease (MRD) is a critical prognostic and therapeutic response marker in multiple myeloma (MM). Two main technologies are used for MRD assessment in bone marrow: next-generation flow cytometry (NGF) and next-g…
View article: A SEGURANÇA E A QUALIDADE DO CUIDADO: O PAPEL DAS TECNOLOGIAS DE IMAGEM E DA COMUNICAÇÃO INTERPROFISSIONAL DO DIAGNÓSTICO À REABILITAÇÃO
A SEGURANÇA E A QUALIDADE DO CUIDADO: O PAPEL DAS TECNOLOGIAS DE IMAGEM E DA COMUNICAÇÃO INTERPROFISSIONAL DO DIAGNÓSTICO À REABILITAÇÃO Open
A segurança do paciente e a qualidade do cuidado são desafios centrais na assistência contemporânea, especialmente diante da crescente complexidade tecnológica dos serviços de saúde. Este estudo teve como objetivo analisar, por meio de uma…
View article: Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression Open
Multiple myeloma (MM) is characterized by the clonal proliferation of plasma cells in the bone marrow. Although the precise molecular mechanisms differentiating men and women in MM are not fully understood, uncovering these differences is …
View article: AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy Open
View article: Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States
Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States Open
Introduction A novel therapy for heavily pretreated triple‐class–exposed multiple myeloma (TCE MM) is B‐cell maturation antigen (BCMA)‐targeted immunotherapy. While the number of TCE+BCMA‐exposed patients is growing, real‐world data for th…
View article: Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting Open
CARTITUDE-4 ClinicalTrials.gov ID: NCT04181827.
View article: Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group Open
Fluorescence in situ hybridization (FISH) remains the gold-standard clinical assay to detect genetic abnormalities in multiple myeloma (MM). However, FISH panel design, use of conventional chromosome banding analysis and reporting practice…
View article: Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions
Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions Open
The treatment of lymphoid malignancies is rapidly advancing with recognition of hypogammaglobulinemia (HG) and increased infection risk with the use of cellular-targeted therapies, such as chimeric antigen receptor (CAR) T cell and bispeci…
View article: Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience Open
View article: A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma
A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma Open
Acquisition of drug resistance, particularly to immunomodulatory drugs (IMiDs) in multiple myeloma (MM), is an important challenge in patient treatment. IMiDs are the canonical molecular glue that bind to cereblon (CRBN) and redirect its E…
View article: Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes Open
View article: Renal, cardiac, and neurologic disease in a patient with Fabry disease, hemizygous for the c.639+5G>C intronic variant in the galactosidase alpha (GLA) gene
Renal, cardiac, and neurologic disease in a patient with Fabry disease, hemizygous for the c.639+5G>C intronic variant in the galactosidase alpha (GLA) gene Open
View article: Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels
Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels Open
View article: Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention Open
Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic strategies to tackle resistance. We conducted a multi-omic characterization of established VTX-resistant isogenic human …
View article: Artificial Intelligence-Enhanced Electrocardiogram
Artificial Intelligence-Enhanced Electrocardiogram Open
Artificial intelligence-enhanced electrocardiogram has emerged as an effective tool for the detection and prognostication of cardiac amyloidosis. In this series, we present 4 cases that demonstrate the potential of the artificial intellige…
View article: Dose delays and treatment interruptions secondary to ocular toxicity from BMCA-directed antibody drug conjugate therapy in relapsed multiple myeloma
Dose delays and treatment interruptions secondary to ocular toxicity from BMCA-directed antibody drug conjugate therapy in relapsed multiple myeloma Open
View article: ÁREAS DE APLICAÇÃO DA METODOLOGIA SEIS SIGMA: UMA ANÁLISE BIBLIOMÉTRICA A PARTIR DAS BASES SCOPUS E WEB OF SCIENCE
ÁREAS DE APLICAÇÃO DA METODOLOGIA SEIS SIGMA: UMA ANÁLISE BIBLIOMÉTRICA A PARTIR DAS BASES SCOPUS E WEB OF SCIENCE Open
View article: Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (<scp>DRd</scp>) Versus Bortezomib, Lenalidomide, and Dexamethasone (<scp>VRd</scp>) Among Transplant‐Ineligible Patients With Multiple Myeloma
Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (<span>DRd</span>) Versus Bortezomib, Lenalidomide, and Dexamethasone (<span>VRd</span>) Among Transplant‐Ineligible Patients With Multiple Myeloma Open
Introduction Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with transplant‐ineligible (TIE) newly diagnosed multiple myeloma …
View article: Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma Open
View article: Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14) Open
View article: Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma
Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma Open
View article: Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies Open
Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical …
View article: Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study
Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study Open
Not available.
View article: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes Open
View article: Immune Effector Cell-Associated Enterocolitis following Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma
Immune Effector Cell-Associated Enterocolitis following Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma Open
Background: Several immune effector cell (IEC) therapies have been approved for multiple myeloma (MM), including chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cil…
View article: IgG replacement in multiple myeloma
IgG replacement in multiple myeloma Open
T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved clinical outcomes, but have also raised awareness for ens…
View article: Performance of newer myeloma staging systems in a contemporary, large patient cohort
Performance of newer myeloma staging systems in a contemporary, large patient cohort Open
View article: Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia Open
PURPOSE Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and MYD88 L265P mutation is now frequently assessed at diagnos…